<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00819923</url>
  </required_header>
  <id_info>
    <org_study_id>SA-003</org_study_id>
    <nct_id>NCT00819923</nct_id>
  </id_info>
  <brief_title>Comparison of Bio-Active-Stent to the Everolimus-Eluting Stent in Acute Coronary Syndrome</brief_title>
  <acronym>BASE-ACS</acronym>
  <official_title>Comparison of Bio-Active-Stent to the Everolimus-Eluting Stent in Acute Coronary Syndrome (A Prospective, Randomized and a Multicenter Clinical Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital District of Satakunta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital District of Satakunta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to compare the safety and effectiveness of bio-active-stent (BAS)
      and everolimus-eluting stent (EES) in patients presenting with acute coronary syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The BASE-ACS trial is an academic study, which will be conceived and conducted as a
      multicenter (multi-country) study by experienced interventional cardiologists. This study is
      independent of commercial interests.

      The purpose of the trial is to compare the safety and effectiveness of bio-active-stent
      (Titan-2®) and everolimus-eluting stent (Xience V®, Promus®) in patients presenting with
      acute coronary syndrome.

      A total of 850 patients will be included in the randomized study. The primary end point
      (MACE) is the composite of cardiac death, myocardial infarction and target lesion
      revascularization during 12 months of follow-up. Enrollment of patients will start in
      November 2008 and end in 2009.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary end point (MACE) is the composite of cardiac death, myocardial infarction (MI) and target lesion revascularization (TLR) during 12 months of follow-up.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause death, cardiac death, MI, stent thrombosis and TLR at 1, 6, 12 and 18 months, and at 2, 3, 4 and 5 years.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">825</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving bio-active stent during the intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving everolimus-eluting stent during the intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous coronary intervention</intervention_name>
    <description>Intra-coronary stenting</description>
    <arm_group_label>1</arm_group_label>
    <other_name>TITAN-2 stent,</other_name>
    <other_name>Hexacath, France</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous coronary intervention</intervention_name>
    <description>Intra-coronary stenting</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Promus (Boston,USA)</other_name>
    <other_name>Xience-V (abbott, Usa)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients presenting with acute coronary syndrome (unstable angina,
             non-st-elevation myocardial infarction or st-elevation myocardial infarction)and
             undergoing percutaneous coronary intervention

          -  Written informed consent

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Expected survival &lt; 1 year

          -  Allergy to aspirin, clopidogrel or ticlopidine

          -  Allergy to heparins, glycoprotein IIb/IIIa inhibitors or bivalirudin

          -  Allergy to everolimus

          -  Active bleeding or significant increased risk of bleeding

          -  Stent length longer than 28 mm needed

          -  Stent diameter &gt; 4.0 mm needed

          -  Thrombolysis therapy

          -  Planned surgery within 12 months of PCI unless the dual antiplatelet therapy could be
             maintained throughout the perisurgical period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pasi P Karjalainen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Satakunta Central Hospital, Pori, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antti Ylitalo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Satakunta Central Hospital, Pori, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matti Niemela, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oulu University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juhani KE Airaksinen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku University Hospital, Turku, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Otto Hess, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bern University Hospital, Bern, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jyvaskyla Central Hospital</name>
      <address>
        <city>Jyvaskyla</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keski-Pohjanmaan Keskusairaala</name>
      <address>
        <city>Kokkola</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <zip>90100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Satakunta Central Hospital</name>
      <address>
        <city>Pori</city>
        <zip>28500</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2009</study_first_submitted>
  <study_first_submitted_qc>January 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2009</study_first_posted>
  <last_update_submitted>May 4, 2011</last_update_submitted>
  <last_update_submitted_qc>May 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Pasi Karjalainen, MD, PhD</name_title>
    <organization>Department of cardiology, Satakunta Central Hospital</organization>
  </responsible_party>
  <keyword>Titanium</keyword>
  <keyword>everolimus</keyword>
  <keyword>drug eluting stent</keyword>
  <keyword>stent thrombosis</keyword>
  <keyword>restenosis</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>acute coronary syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 1, 2015</submitted>
    <returned>June 17, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

